Fri, Dec 26, 2014, 1:02 AM EST - U.S. Markets open in 8 hrs 28 mins

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

chinesehamsters 2 posts  |  Last Activity: Oct 13, 2014 6:20 PM Member since: Sep 24, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • chinesehamsters chinesehamsters Oct 13, 2014 6:20 PM Flag

    Way back before Kadcyla obtained its first approval I had been watching this company and bought into it based on the strength of the clinical data as it became available. My cost basis was around $7. I made the right decision to set the money aside and go back to cash when we were around $12ish. The current weakness aside from the overall market makes me wonder if there is another secondary offering in the works. Higher roylaties from Kadcyla are still further out, and licensing fees are not just flying off the shelves either. I will continue to sit on the side lines, but at some point this has to become such a compelling value that some one buys them, or the alternative is the board has no choice but to get rid of Junius. Not even those fat cats can justify keeping this current manamgement in place.

    Chinese Hamsters

  • Reply to

    Poor Charlie's financial hardship

    by bioimmunomabman Sep 30, 2014 3:00 PM
    chinesehamsters chinesehamsters Oct 2, 2014 12:21 PM Flag

    Really, they are giving Morris $125K to help defray the costs of a 2nd residence in Mass where the company headquarters is located, while he keeps his primary residence in Pennsylvania. So isn't that his choice? Do they offer that kind of housing assistance to all of the employees, umm no. Is Morris so remarkable that he should be catered to? I have not seen anything remarkable about him. I have not seen anything remarkable about any of the IMGN leadership team. These guys are like vampires sucking the company drie until it is a corpse.

    Off topic. The Ebola situation and that is has shown up in the United States now may provide some unique investment opportunties. Look over some of the players in that space. The FDA has a special situational path to approval for drugs in early stages of development that will allow human use pretty much without going through any clinical trials. I think it is termed the animal model, they can do a safety and dose escalating study in monkeys and if that looks OK they can proceed directly to human use. Sad that a situation like this has to develop to focus all the resources needed to curb this disease.

    Chinese Hamsters

CRIS
1.29+0.04(+3.20%)Dec 24 12:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Gilead Sciences Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST